13.15
前日終値:
$12.94
開ける:
$12.99
24時間の取引高:
730.51K
Relative Volume:
2.57
時価総額:
$657.52M
収益:
$62.02M
当期純損益:
$-45.65M
株価収益率:
-14.29
EPS:
-0.92
ネットキャッシュフロー:
$-9.60M
1週間 パフォーマンス:
+14.15%
1か月 パフォーマンス:
+14.05%
6か月 パフォーマンス:
+36.84%
1年 パフォーマンス:
+59.39%
Theravance Biopharma Inc Stock (TBPH) Company Profile
名前
Theravance Biopharma Inc
セクター
電話
650-808-6000
住所
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
TBPH を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
TBPH
Theravance Biopharma Inc
|
13.15 | 652.18M | 62.02M | -45.65M | -9.60M | -0.92 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-08-06 | ダウングレード | Leerink Partners | Outperform → Market Perform |
2024-04-12 | 開始されました | BTIG Research | Buy |
2024-01-08 | ダウングレード | Evercore ISI | Outperform → In-line |
2022-05-23 | 開始されました | SVB Leerink | Outperform |
2021-11-05 | アップグレード | JP Morgan | Underweight → Neutral |
2021-09-15 | ダウングレード | JP Morgan | Overweight → Underweight |
2021-08-25 | ダウングレード | Morgan Stanley | Overweight → Underweight |
2021-08-24 | ダウングレード | Cowen | Outperform → Market Perform |
2020-10-14 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2020-07-07 | 開始されました | JP Morgan | Overweight |
2020-06-15 | 開始されました | Morgan Stanley | Equal-Weight |
2020-05-13 | 開始されました | Cowen | Outperform |
2020-01-08 | 繰り返されました | H.C. Wainwright | Buy |
2019-11-06 | アップグレード | Robert W. Baird | Underperform → Neutral |
2019-10-29 | 開始されました | H.C. Wainwright | Buy |
2018-03-29 | 再開されました | Piper Jaffray | Overweight |
2017-08-17 | 開始されました | Evercore ISI | Outperform |
2017-06-16 | 開始されました | Cantor Fitzgerald | Overweight |
2017-05-11 | 繰り返されました | Needham | Buy |
2016-12-21 | 開始されました | Needham | Buy |
2016-11-03 | 開始されました | Piper Jaffray | Overweight |
2016-10-12 | ダウングレード | Robert W. Baird | Neutral → Underperform |
2016-08-03 | ダウングレード | BofA/Merrill | Neutral → Underperform |
2016-06-20 | 開始されました | Guggenheim | Buy |
2016-06-20 | 繰り返されました | Leerink Partners | Outperform |
2016-05-12 | 開始されました | Leerink Partners | Outperform |
2016-05-05 | ダウングレード | BofA/Merrill | Buy → Neutral |
2015-02-03 | アップグレード | Robert W. Baird | Underperform → Neutral |
すべてを表示
Theravance Biopharma Inc (TBPH) 最新ニュース
What makes Theravance Biopharma Inc. stock price move sharplyJuly 2025 Snapshot & Short-Term Trading Opportunity Alerts - thegnnews.com
Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN
H.C. Wainwright Sticks to Their Buy Rating for Theravance Biopharma (TBPH) - The Globe and Mail
The 11% Return This Week Takes Theravance Biopharma's (NASDAQ:TBPH) Shareholders One-year Gains to 51% - 富途牛牛
Theravance Biopharma Second Quarter 2025 Earnings: EPS Beats Expectations - uk.finance.yahoo.com
Theravance Biopharma (NASDAQ:TBPH) shareholder returns have been respectable, earning 51% in 1 year - simplywall.st
Theravance Biopharma, Inc. SEC 10-Q Report - TradingView
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2025 Earnings Call Transcript - Insider Monkey
Theravance Biopharma stock price target raised to $13 by Leerink Partners By Investing.com - Investing.com Nigeria
Theravance Biopharma stock price target raised to $13 by Leerink Partners - Investing.com UK
Theravance Biopharma Q2 2025 Earnings Call Transcript - MarketBeat
Theravance Biopharma Inc (TBPH) Q2 2025 Earnings Call Highlights: Strong Sales and Strategic ... - Yahoo Finance
Theravance Sales Jump 83 Percent - AOL.com
Theravance anticipates $150M in milestones as CYPRESS trial nears pivotal data readout - MSN
Technical signs of recovery in Theravance Biopharma Inc. [Analyst Upgrade]Free Safe Entry Momentum Stock Tips - Newser
Theravance Biopharma Reports Strong Q2 2025 Results - TipRanks
Theravance Bio: Q2 Earnings Snapshot - Big Rapids Pioneer
Theravance Sales Jump 83 Percent - The Motley Fool
Theravance Biopharma (TBPH): A High-Conviction Play on Rare Disease Innovation and Durable Cash Flow - AInvest
Contradictions Unveiled: Theravance Biopharma's 2025Q2 Earnings Call Highlights Pricing, Strategy, and Market Dynamics - AInvest
Theravance Biopharma's Q2 Surge: A Case Study in Biotech Resilience and Strategic Precision - AInvest
Earnings call transcript: Theravance Biopharma Q2 2025 earnings beat expectations - Investing.com
What institutional flow reveals about Theravance Biopharma Inc.Trade Safety Matrix for Conservative Traders - Newser
Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Theravance Biopharma Q2 2025 slides: Revenue jumps 22%, cash position triples - Investing.com Canada
Theravance Biopharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
THERAVANCE BIOPHARMA Earnings Results: $TBPH Reports Quarterly Earnings - Quiver Quantitative
Theravance Biopharma earnings beat by $0.41, revenue topped estimates - Investing.com Canada
Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
Is Theravance Biopharma Inc. still worth holding after the dipFree Smart Money Tracking Signal Generator - Newser
Technical signs of recovery in Theravance Biopharma Inc.Daily Profit Watch With Forecast Confidence - Newser
Theravance Biopharma Inc.’s volatility index tracking explainedTrend Confirmation Scanner with Entry Focus - Newser
Signal strength of Theravance Biopharma Inc. stock in tech scannersRisk Aware Trading Ideas with Alert Levels - Newser
Real time pattern detection on Theravance Biopharma Inc. stockIntraday Signal Forecast for Fast Traders - Newser
Price momentum metrics for Theravance Biopharma Inc. explainedFree News Based Entry Opportunity Alerts - Newser
Tools to monitor Theravance Biopharma Inc. recovery probabilitySwing Watchlist With Tight Stop Placement - Newser
Using data models to predict Theravance Biopharma Inc. stock movementSmart Stock Forecast Using AI Algorithms - Newser
Theravance Biopharma (TBPH) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Moving Average Trends for Theravance Biopharma Inc. Stock: What They IndicateTechnical Entry Plan with Risk Minimization - Newser
Theravance Biopharma Inc expected to post earnings of 67 cents a shareEarnings Preview - TradingView
Theravance Biopharma Inc. Stock Performance After Earnings: Historical InsightsFree Conservative Entry for High Return Setup - Newser
How Theravance Biopharma Inc. stock performs during market volatilitySmart Trade Forecast Based on Neural Logic - Newser
Technical Charts Suggest Momentum Shift in Theravance Biopharma Inc.Chart Driven Price Action Analysis - beatles.ru
What’s the recovery path for long term holders of Theravance Biopharma Inc.Free ROI Boosting Trade Opportunity Calendar - Newser
What is the dividend policy of Theravance Biopharma Inc. stockInvest confidently with professional market insights - Jammu Links News
Is Theravance Biopharma Inc. stock overvalued or undervaluedInvest confidently with actionable market data - Jammu Links News
What are the latest earnings results for Theravance Biopharma Inc.Maximize gains with timely market signals - Jammu Links News
What are the technical indicators suggesting about Theravance Biopharma Inc.High-velocity gains - Jammu Links News
How volatile is Theravance Biopharma Inc. stock compared to the marketBreakthrough profits - Jammu Links News
What analysts say about Theravance Biopharma Inc. stockSuperior returns - Jammu Links News
Should I hold or sell Theravance Biopharma Inc. stock in 2025Build a diversified portfolio for risk management - Jammu Links News
Theravance Biopharma Inc (TBPH) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):